Aerovate Q1 net loss $10.9M; Phase 2b PAH trial topline data expected Q4 2023/Q1 2024

Jade Biosciences, Inc.

2023-Q1 EPS reported -$0.45

Net loss Q1 2022 $10.9M vs $2.8M in 2021; R&D up to $7.3M, G&A up to $3.8M.
Cash and investments $161.1M; cash runway into second half of 2025.
Site initiation delays push Phase 2b topline data from IMPAHCT trial to Q4 2023 or Q1 2024.
Hired Marco Verwijs as SVP CMC and Susan Fischer as SVP Development Operations.
Expanded IP portfolio with new U.S. patent and allowances.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.